CA2470844A1

CA2470844A1 - Novel compositions and methods for cancer

Novel compositions and methods for cancer Download PDF

Info

Publication number: CA2470844A1
Authority: CA; Canada
Prior art keywords: protein; nucleic acid; gene; sequences; expression
Prior art date: 2001-12-20
Legal status : Abandoned

Application number

CA002470844A

Other languages

English (en)

French (fr)

Inventor

David W. Morris

Current Assignee

Sagres Discovery Inc

Original Assignee

Individual

Priority date

2001-12-20

Filing date

2002-12-20

Publication date

2003-07-03

2002-12-20 Application filed by Individual filed Critical Individual

2003-07-03 Publication of CA2470844A1 publication Critical patent/CA2470844A1/en

Status Abandoned legal-status Critical Current

Links

238000000034 method Methods 0.000 title claims abstract description 134
239000000203 mixture Substances 0.000 title abstract description 23
206010028980 Neoplasm Diseases 0.000 title description 47
201000011510 cancer Diseases 0.000 title description 18
201000009030 Carcinoma Diseases 0.000 claims abstract description 81
238000012216 screening Methods 0.000 claims abstract description 36
108090000623 proteins and genes Proteins 0.000 claims description 454
102000004169 proteins and genes Human genes 0.000 claims description 310
150000007523 nucleic acids Chemical class 0.000 claims description 154
102000039446 nucleic acids Human genes 0.000 claims description 126
108020004707 nucleic acids Proteins 0.000 claims description 126
230000014509 gene expression Effects 0.000 claims description 106
230000027455 binding Effects 0.000 claims description 69
238000009739 binding Methods 0.000 claims description 69
239000003795 chemical substances by application Substances 0.000 claims description 69
108090000765 processed proteins & peptides Proteins 0.000 claims description 68
239000000523 sample Substances 0.000 claims description 67
230000000694 effects Effects 0.000 claims description 66
102000004196 processed proteins & peptides Human genes 0.000 claims description 56
239000012867 bioactive agent Substances 0.000 claims description 44
229920001184 polypeptide Polymers 0.000 claims description 44
239000013604 expression vector Substances 0.000 claims description 25
239000012634 fragment Substances 0.000 claims description 23
125000003275 alpha amino acid group Chemical group 0.000 claims description 22
108020004414 DNA Proteins 0.000 claims description 21
125000003729 nucleotide group Chemical group 0.000 claims description 21
108091028043 Nucleic acid sequence Proteins 0.000 claims description 20
238000000018 DNA microarray Methods 0.000 claims description 18
238000009396 hybridization Methods 0.000 claims description 18
239000002773 nucleotide Substances 0.000 claims description 18
229940000406 drug candidate Drugs 0.000 claims description 17
239000003814 drug Substances 0.000 claims description 10
230000004075 alteration Effects 0.000 claims description 9
239000003112 inhibitor Substances 0.000 claims description 9
229940079593 drug Drugs 0.000 claims description 8
230000002401 inhibitory effect Effects 0.000 claims description 7
230000004913 activation Effects 0.000 claims description 6
238000012163 sequencing technique Methods 0.000 claims description 4
108010008281 Recombinant Fusion Proteins Proteins 0.000 claims description 3
102000007056 Recombinant Fusion Proteins Human genes 0.000 claims description 3
238000006386 neutralization reaction Methods 0.000 claims description 2
230000003472 neutralizing effect Effects 0.000 claims description 2
206010025323 Lymphomas Diseases 0.000 abstract description 29
238000011282 treatment Methods 0.000 abstract description 13
238000003745 diagnosis Methods 0.000 abstract description 11
235000018102 proteins Nutrition 0.000 description 296
210000004027 cell Anatomy 0.000 description 118
241000282414 Homo sapiens Species 0.000 description 91
241000699666 Mus <mouse, genus> Species 0.000 description 69
108020004999 messenger RNA Proteins 0.000 description 43
238000003556 assay Methods 0.000 description 38
210000001519 tissue Anatomy 0.000 description 37
108091026890 Coding region Proteins 0.000 description 28
235000001014 amino acid Nutrition 0.000 description 26
230000003211 malignant effect Effects 0.000 description 23
150000001413 amino acids Chemical class 0.000 description 21
-1 carbocyclic sugars Chemical class 0.000 description 20
230000001105 regulatory effect Effects 0.000 description 19
238000003780 insertion Methods 0.000 description 17
230000037431 insertion Effects 0.000 description 17
108020004711 Nucleic Acid Probes Proteins 0.000 description 16
230000000692 anti-sense effect Effects 0.000 description 16
150000001875 compounds Chemical class 0.000 description 16
239000002853 nucleic acid probe Substances 0.000 description 16
239000007787 solid Substances 0.000 description 16
230000003834 intracellular effect Effects 0.000 description 15
238000006467 substitution reaction Methods 0.000 description 15
108091034117 Oligonucleotide Proteins 0.000 description 14
150000003839 salts Chemical class 0.000 description 14
102000035160 transmembrane proteins Human genes 0.000 description 13
108091005703 transmembrane proteins Proteins 0.000 description 13
208000032839 leukemia Diseases 0.000 description 12
239000000126 substance Substances 0.000 description 12
108060003951 Immunoglobulin Proteins 0.000 description 11
241001465754 Metazoa Species 0.000 description 11
102000052575 Proto-Oncogene Human genes 0.000 description 11
108700020978 Proto-Oncogene Proteins 0.000 description 11
230000000295 complement effect Effects 0.000 description 11
238000001514 detection method Methods 0.000 description 11
102000018358 immunoglobulin Human genes 0.000 description 11
108010041986 DNA Vaccines Proteins 0.000 description 10
230000001580 bacterial effect Effects 0.000 description 10
239000003153 chemical reaction reagent Substances 0.000 description 10
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
239000003446 ligand Substances 0.000 description 10
239000002777 nucleoside Substances 0.000 description 10
229940021995 DNA vaccine Drugs 0.000 description 9
239000000427 antigen Substances 0.000 description 9
102000036639 antigens Human genes 0.000 description 9
108091007433 antigens Proteins 0.000 description 9
230000015572 biosynthetic process Effects 0.000 description 9
201000010099 disease Diseases 0.000 description 9
238000005516 engineering process Methods 0.000 description 9
238000000338 in vitro Methods 0.000 description 9
230000004048 modification Effects 0.000 description 9
238000012986 modification Methods 0.000 description 9
230000035772 mutation Effects 0.000 description 9
238000004393 prognosis Methods 0.000 description 9
102000005962 receptors Human genes 0.000 description 9
108020003175 receptors Proteins 0.000 description 9
239000013598 vector Substances 0.000 description 9
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 8
239000002253 acid Substances 0.000 description 8
239000002671 adjuvant Substances 0.000 description 8
238000003491 array Methods 0.000 description 8
238000006243 chemical reaction Methods 0.000 description 8
230000000875 corresponding effect Effects 0.000 description 8
239000003623 enhancer Substances 0.000 description 8
239000013615 primer Substances 0.000 description 8
230000001225 therapeutic effect Effects 0.000 description 8
238000005406 washing Methods 0.000 description 8
108700020796 Oncogene Proteins 0.000 description 7
108010090804 Streptavidin Proteins 0.000 description 7
208000009956 adenocarcinoma Diseases 0.000 description 7
238000004458 analytical method Methods 0.000 description 7
230000004071 biological effect Effects 0.000 description 7
150000001720 carbohydrates Chemical class 0.000 description 7
238000012217 deletion Methods 0.000 description 7
230000037430 deletion Effects 0.000 description 7
230000002255 enzymatic effect Effects 0.000 description 7
229940124452 immunizing agent Drugs 0.000 description 7
230000001965 increasing effect Effects 0.000 description 7
238000011002 quantification Methods 0.000 description 7
238000013518 transcription Methods 0.000 description 7
230000035897 transcription Effects 0.000 description 7
241001430294 unidentified retrovirus Species 0.000 description 7
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 6
241000894006 Bacteria Species 0.000 description 6
241000124008 Mammalia Species 0.000 description 6
102000043276 Oncogene Human genes 0.000 description 6
239000002246 antineoplastic agent Substances 0.000 description 6
238000004422 calculation algorithm Methods 0.000 description 6
230000001413 cellular effect Effects 0.000 description 6
230000008859 change Effects 0.000 description 6
229940127089 cytotoxic agent Drugs 0.000 description 6
230000007423 decrease Effects 0.000 description 6
238000011156 evaluation Methods 0.000 description 6
125000000524 functional group Chemical group 0.000 description 6
230000004927 fusion Effects 0.000 description 6
238000001415 gene therapy Methods 0.000 description 6
230000013595 glycosylation Effects 0.000 description 6
238000006206 glycosylation reaction Methods 0.000 description 6
230000012010 growth Effects 0.000 description 6
238000011534 incubation Methods 0.000 description 6
239000000463 material Substances 0.000 description 6
238000012544 monitoring process Methods 0.000 description 6
150000003833 nucleoside derivatives Chemical class 0.000 description 6
238000000746 purification Methods 0.000 description 6
238000007423 screening assay Methods 0.000 description 6
230000002103 transcriptional effect Effects 0.000 description 6
108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
241000238631 Hexapoda Species 0.000 description 5
108091005461 Nucleic proteins Chemical group 0.000 description 5
240000004808 Saccharomyces cerevisiae Species 0.000 description 5
235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 5
241000700605 Viruses Species 0.000 description 5
150000001412 amines Chemical group 0.000 description 5
125000000539 amino acid group Chemical group 0.000 description 5
238000010171 animal model Methods 0.000 description 5
239000002254 cytotoxic agent Substances 0.000 description 5
231100000599 cytotoxic agent Toxicity 0.000 description 5
230000006870 function Effects 0.000 description 5
239000003102 growth factor Substances 0.000 description 5
210000004408 hybridoma Anatomy 0.000 description 5
238000003018 immunoassay Methods 0.000 description 5
238000009169 immunotherapy Methods 0.000 description 5
230000003993 interaction Effects 0.000 description 5
125000003835 nucleoside group Chemical group 0.000 description 5
235000013930 proline Nutrition 0.000 description 5
239000000758 substrate Substances 0.000 description 5
108091003079 Bovine Serum Albumin Proteins 0.000 description 4
208000005623 Carcinogenesis Diseases 0.000 description 4
102000000844 Cell Surface Receptors Human genes 0.000 description 4
108010001857 Cell Surface Receptors Proteins 0.000 description 4
108020004705 Codon Proteins 0.000 description 4
102000004127 Cytokines Human genes 0.000 description 4
108090000695 Cytokines Proteins 0.000 description 4
102000053602 DNA Human genes 0.000 description 4
102000004190 Enzymes Human genes 0.000 description 4
108090000790 Enzymes Proteins 0.000 description 4
ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 4
208000017604 Hodgkin disease Diseases 0.000 description 4
241000282412 Homo Species 0.000 description 4
108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 4
ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 4
241000699670 Mus sp. Species 0.000 description 4
208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 4
206010035226 Plasma cell myeloma Diseases 0.000 description 4
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 4
241000283984 Rodentia Species 0.000 description 4
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
125000003277 amino group Chemical group 0.000 description 4
229940098773 bovine serum albumin Drugs 0.000 description 4
230000036952 cancer formation Effects 0.000 description 4
231100000504 carcinogenesis Toxicity 0.000 description 4
235000018417 cysteine Nutrition 0.000 description 4
230000003247 decreasing effect Effects 0.000 description 4
230000003828 downregulation Effects 0.000 description 4
108020001507 fusion proteins Proteins 0.000 description 4
102000037865 fusion proteins Human genes 0.000 description 4
239000000499 gel Substances 0.000 description 4
239000011521 glass Substances 0.000 description 4
230000002209 hydrophobic effect Effects 0.000 description 4
FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 4
238000003384 imaging method Methods 0.000 description 4
230000002163 immunogen Effects 0.000 description 4
230000006698 induction Effects 0.000 description 4
125000005647 linker group Chemical group 0.000 description 4
210000003563 lymphoid tissue Anatomy 0.000 description 4
210000004962 mammalian cell Anatomy 0.000 description 4
201000001441 melanoma Diseases 0.000 description 4
239000012528 membrane Substances 0.000 description 4
108091005573 modified proteins Proteins 0.000 description 4
102000035118 modified proteins Human genes 0.000 description 4
239000008194 pharmaceutical composition Substances 0.000 description 4
230000004044 response Effects 0.000 description 4
150000003384 small molecules Chemical class 0.000 description 4
239000000243 solution Substances 0.000 description 4
230000009870 specific binding Effects 0.000 description 4
238000003786 synthesis reaction Methods 0.000 description 4
125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 4
235000002374 tyrosine Nutrition 0.000 description 4
125000001493 tyrosinyl group Chemical class [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
206010003571 Astrocytoma Diseases 0.000 description 3
208000010747 Hodgkins lymphoma Diseases 0.000 description 3
102100029098 Hypoxanthine-guanine phosphoribosyltransferase Human genes 0.000 description 3
239000004677 Nylon Substances 0.000 description 3
108700026244 Open Reading Frames Proteins 0.000 description 3
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
108091005804 Peptidases Proteins 0.000 description 3
239000002202 Polyethylene glycol Substances 0.000 description 3
239000004365 Protease Substances 0.000 description 3
102000001253 Protein Kinase Human genes 0.000 description 3
108010076504 Protein Sorting Signals Proteins 0.000 description 3
241000700159 Rattus Species 0.000 description 3
102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 3
102000014400 SH2 domains Human genes 0.000 description 3
108050003452 SH2 domains Proteins 0.000 description 3
206010039491 Sarcoma Diseases 0.000 description 3
108700019146 Transgenes Proteins 0.000 description 3
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
108700005077 Viral Genes Proteins 0.000 description 3
230000003321 amplification Effects 0.000 description 3
239000005557 antagonist Substances 0.000 description 3
238000013459 approach Methods 0.000 description 3
239000011230 binding agent Substances 0.000 description 3
230000000975 bioactive effect Effects 0.000 description 3
229960002685 biotin Drugs 0.000 description 3
235000020958 biotin Nutrition 0.000 description 3
239000011616 biotin Substances 0.000 description 3
239000000872 buffer Substances 0.000 description 3
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
230000032823 cell division Effects 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
238000010367 cloning Methods 0.000 description 3
239000002299 complementary DNA Substances 0.000 description 3
230000004069 differentiation Effects 0.000 description 3
238000006073 displacement reaction Methods 0.000 description 3
239000000975 dye Substances 0.000 description 3
238000004520 electroporation Methods 0.000 description 3
239000000284 extract Substances 0.000 description 3
150000004676 glycans Chemical class 0.000 description 3
239000001963 growth medium Substances 0.000 description 3
238000013537 high throughput screening Methods 0.000 description 3
238000003119 immunoblot Methods 0.000 description 3
238000011065 in-situ storage Methods 0.000 description 3
230000001939 inductive effect Effects 0.000 description 3
238000009830 intercalation Methods 0.000 description 3
210000004698 lymphocyte Anatomy 0.000 description 3
239000011159 matrix material Substances 0.000 description 3
210000004379 membrane Anatomy 0.000 description 3
210000000214 mouth Anatomy 0.000 description 3
238000002703 mutagenesis Methods 0.000 description 3
231100000350 mutagenesis Toxicity 0.000 description 3
238000003199 nucleic acid amplification method Methods 0.000 description 3
229920001778 nylon Polymers 0.000 description 3
229920001223 polyethylene glycol Polymers 0.000 description 3
229920001282 polysaccharide Polymers 0.000 description 3
239000005017 polysaccharide Substances 0.000 description 3
238000000159 protein binding assay Methods 0.000 description 3
108060006633 protein kinase Proteins 0.000 description 3
230000004850 protein–protein interaction Effects 0.000 description 3
230000001177 retroviral effect Effects 0.000 description 3
230000003248 secreting effect Effects 0.000 description 3
230000028327 secretion Effects 0.000 description 3
125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 3
238000010561 standard procedure Methods 0.000 description 3
230000008685 targeting Effects 0.000 description 3
239000003053 toxin Substances 0.000 description 3
231100000765 toxin Toxicity 0.000 description 3
108700012359 toxins Proteins 0.000 description 3
230000004614 tumor growth Effects 0.000 description 3
230000003827 upregulation Effects 0.000 description 3
HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
VPFUWHKTPYPNGT-UHFFFAOYSA-N 3-(3,4-dihydroxyphenyl)-1-(5-hydroxy-2,2-dimethylchromen-6-yl)propan-1-one Chemical compound OC1=C2C=CC(C)(C)OC2=CC=C1C(=O)CCC1=CC=C(O)C(O)=C1 VPFUWHKTPYPNGT-UHFFFAOYSA-N 0.000 description 2
LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
108010088751 Albumins Proteins 0.000 description 2
102000009027 Albumins Human genes 0.000 description 2
102000002260 Alkaline Phosphatase Human genes 0.000 description 2
108020004774 Alkaline Phosphatase Proteins 0.000 description 2
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
241000193830 Bacillus <bacterium> Species 0.000 description 2
244000063299 Bacillus subtilis Species 0.000 description 2
235000014469 Bacillus subtilis Nutrition 0.000 description 2
241000283690 Bos taurus Species 0.000 description 2
206010006187 Breast cancer Diseases 0.000 description 2
208000026310 Breast neoplasm Diseases 0.000 description 2
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
201000000274 Carcinosarcoma Diseases 0.000 description 2
108010078791 Carrier Proteins Proteins 0.000 description 2
102000014914 Carrier Proteins Human genes 0.000 description 2
208000005243 Chondrosarcoma Diseases 0.000 description 2
241000699800 Cricetinae Species 0.000 description 2
239000004971 Cross linker Substances 0.000 description 2
239000003155 DNA primer Substances 0.000 description 2
102000001301 EGF receptor Human genes 0.000 description 2
108060006698 EGF receptor Proteins 0.000 description 2
238000002965 ELISA Methods 0.000 description 2
241000196324 Embryophyta Species 0.000 description 2
ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
241000588724 Escherichia coli Species 0.000 description 2
201000008808 Fibrosarcoma Diseases 0.000 description 2
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
239000004471 Glycine Substances 0.000 description 2
AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
108010031186 Glycoside Hydrolases Proteins 0.000 description 2
102000005744 Glycoside Hydrolases Human genes 0.000 description 2
101000686034 Homo sapiens Nuclear receptor ROR-gamma Proteins 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 2
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
229930010555 Inosine Natural products 0.000 description 2
UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 2
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
208000007766 Kaposi sarcoma Diseases 0.000 description 2
101150057135 Kcnj9 gene Proteins 0.000 description 2
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
206010024305 Leukaemia monocytic Diseases 0.000 description 2
208000028018 Lymphocytic leukaemia Diseases 0.000 description 2
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
239000004472 Lysine Substances 0.000 description 2
OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
206010027145 Melanocytic naevus Diseases 0.000 description 2
206010027406 Mesothelioma Diseases 0.000 description 2
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
208000034578 Multiple myelomas Diseases 0.000 description 2
241001529936 Murinae Species 0.000 description 2
241000714177 Murine leukemia virus Species 0.000 description 2
239000000020 Nitrocellulose Substances 0.000 description 2
101710163270 Nuclease Proteins 0.000 description 2
201000010133 Oligodendroglioma Diseases 0.000 description 2
108010038807 Oligopeptides Proteins 0.000 description 2
102000015636 Oligopeptides Human genes 0.000 description 2
108091093037 Peptide nucleic acid Proteins 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
239000004698 Polyethylene Substances 0.000 description 2
239000004793 Polystyrene Substances 0.000 description 2
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
241000700584 Simplexvirus Species 0.000 description 2
208000000453 Skin Neoplasms Diseases 0.000 description 2
FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 2
PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
102000044209 Tumor Suppressor Genes Human genes 0.000 description 2
108700025716 Tumor Suppressor Genes Proteins 0.000 description 2
ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
230000009471 action Effects 0.000 description 2
OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
238000001042 affinity chromatography Methods 0.000 description 2
239000000556 agonist Substances 0.000 description 2
230000002707 ameloblastic effect Effects 0.000 description 2
239000004599 antimicrobial Substances 0.000 description 2
239000000074 antisense oligonucleotide Substances 0.000 description 2
238000012230 antisense oligonucleotides Methods 0.000 description 2
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
230000001588 bifunctional effect Effects 0.000 description 2
230000008827 biological function Effects 0.000 description 2
230000000903 blocking effect Effects 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000008280 blood Substances 0.000 description 2
239000011575 calcium Substances 0.000 description 2
229910052791 calcium Inorganic materials 0.000 description 2
235000014633 carbohydrates Nutrition 0.000 description 2
229910052799 carbon Inorganic materials 0.000 description 2
230000015556 catabolic process Effects 0.000 description 2
238000004587 chromatography analysis Methods 0.000 description 2
230000002759 chromosomal effect Effects 0.000 description 2
208000009060 clear cell adenocarcinoma Diseases 0.000 description 2
230000002860 competitive effect Effects 0.000 description 2
230000001268 conjugating effect Effects 0.000 description 2
108091036078 conserved sequence Proteins 0.000 description 2
230000008878 coupling Effects 0.000 description 2
238000010168 coupling process Methods 0.000 description 2
238000005859 coupling reaction Methods 0.000 description 2
238000004132 cross linking Methods 0.000 description 2
230000009260 cross reactivity Effects 0.000 description 2
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
150000001945 cysteines Chemical class 0.000 description 2
108010057085 cytokine receptors Proteins 0.000 description 2
102000003675 cytokine receptors Human genes 0.000 description 2
OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
238000006731 degradation reaction Methods 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
239000003599 detergent Substances 0.000 description 2
238000011161 development Methods 0.000 description 2
230000018109 developmental process Effects 0.000 description 2
238000002405 diagnostic procedure Methods 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 2
BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 2
238000007878 drug screening assay Methods 0.000 description 2
230000000668 effect on calcium Effects 0.000 description 2
230000002124 endocrine Effects 0.000 description 2
150000002148 esters Chemical class 0.000 description 2
239000007850 fluorescent dye Substances 0.000 description 2
238000009472 formulation Methods 0.000 description 2
230000002538 fungal effect Effects 0.000 description 2
210000004392 genitalia Anatomy 0.000 description 2
125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 2
229930004094 glycosylphosphatidylinositol Natural products 0.000 description 2
UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
238000003306 harvesting Methods 0.000 description 2
235000014304 histidine Nutrition 0.000 description 2
125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 2
238000002744 homologous recombination Methods 0.000 description 2
230000006801 homologous recombination Effects 0.000 description 2
210000005260 human cell Anatomy 0.000 description 2
125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
230000001900 immune effect Effects 0.000 description 2
230000028993 immune response Effects 0.000 description 2
230000003053 immunization Effects 0.000 description 2
238000002649 immunization Methods 0.000 description 2
229940072221 immunoglobulins Drugs 0.000 description 2
230000008676 import Effects 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
238000010348 incorporation Methods 0.000 description 2
208000015181 infectious disease Diseases 0.000 description 2
229960003786 inosine Drugs 0.000 description 2
230000010354 integration Effects 0.000 description 2
DRAVOWXCEBXPTN-UHFFFAOYSA-N isoguanine Chemical compound NC1=NC(=O)NC2=C1NC=N2 DRAVOWXCEBXPTN-UHFFFAOYSA-N 0.000 description 2
210000000244 kidney pelvis Anatomy 0.000 description 2
239000007791 liquid phase Substances 0.000 description 2
230000004807 localization Effects 0.000 description 2
208000003747 lymphoid leukemia Diseases 0.000 description 2
239000003550 marker Substances 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
230000001404 mediated effect Effects 0.000 description 2
238000002844 melting Methods 0.000 description 2
TWXDDNPPQUTEOV-FVGYRXGTSA-N methamphetamine hydrochloride Chemical compound Cl.CN[C@@H](C)CC1=CC=CC=C1 TWXDDNPPQUTEOV-FVGYRXGTSA-N 0.000 description 2
201000006894 monocytic leukemia Diseases 0.000 description 2
208000025113 myeloid leukemia Diseases 0.000 description 2
201000000050 myeloid neoplasm Diseases 0.000 description 2
229930014626 natural product Natural products 0.000 description 2
239000013642 negative control Substances 0.000 description 2
210000000653 nervous system Anatomy 0.000 description 2
230000007935 neutral effect Effects 0.000 description 2
229920001220 nitrocellulos Polymers 0.000 description 2
230000009871 nonspecific binding Effects 0.000 description 2
150000002894 organic compounds Chemical class 0.000 description 2
239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
239000002831 pharmacologic agent Substances 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
210000003800 pharynx Anatomy 0.000 description 2
150000003904 phospholipids Chemical class 0.000 description 2
230000026731 phosphorylation Effects 0.000 description 2
238000006366 phosphorylation reaction Methods 0.000 description 2
239000004033 plastic Substances 0.000 description 2
229920003023 plastic Polymers 0.000 description 2
230000008488 polyadenylation Effects 0.000 description 2
108091033319 polynucleotide Proteins 0.000 description 2
102000040430 polynucleotide Human genes 0.000 description 2
239000002157 polynucleotide Substances 0.000 description 2
229920002223 polystyrene Polymers 0.000 description 2
229910052700 potassium Inorganic materials 0.000 description 2
239000011591 potassium Substances 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
230000001566 pro-viral effect Effects 0.000 description 2
230000000750 progressive effect Effects 0.000 description 2
230000035755 proliferation Effects 0.000 description 2
230000004952 protein activity Effects 0.000 description 2
150000003212 purines Chemical class 0.000 description 2
230000005855 radiation Effects 0.000 description 2
230000002285 radioactive effect Effects 0.000 description 2
102000027426 receptor tyrosine kinases Human genes 0.000 description 2
108091008598 receptor tyrosine kinases Proteins 0.000 description 2
238000010188 recombinant method Methods 0.000 description 2
230000010076 replication Effects 0.000 description 2
238000011160 research Methods 0.000 description 2
YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
235000004400 serine Nutrition 0.000 description 2
239000000377 silicon dioxide Substances 0.000 description 2
229910052708 sodium Inorganic materials 0.000 description 2
239000011734 sodium Substances 0.000 description 2
229910001415 sodium ion Inorganic materials 0.000 description 2
239000007790 solid phase Substances 0.000 description 2
RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
238000001890 transfection Methods 0.000 description 2
230000009466 transformation Effects 0.000 description 2
230000009261 transgenic effect Effects 0.000 description 2
238000013519 translation Methods 0.000 description 2
GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
230000002485 urinary effect Effects 0.000 description 2
210000004291 uterus Anatomy 0.000 description 2
230000003612 virological effect Effects 0.000 description 2
HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
FXYPGCIGRDZWNR-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-[[3-(2,5-dioxopyrrolidin-1-yl)oxy-3-oxopropyl]disulfanyl]propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCSSCCC(=O)ON1C(=O)CCC1=O FXYPGCIGRDZWNR-UHFFFAOYSA-N 0.000 description 1
QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
125000003287 1H-imidazol-4-ylmethyl group Chemical group [H]N1C([H])=NC(C([H])([H])[*])=C1[H] 0.000 description 1
150000003923 2,5-pyrrolediones Chemical class 0.000 description 1
XQCZBXHVTFVIFE-UHFFFAOYSA-N 2-amino-4-hydroxypyrimidine Chemical compound NC1=NC=CC(O)=N1 XQCZBXHVTFVIFE-UHFFFAOYSA-N 0.000 description 1
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
BIGBDMFRWJRLGJ-UHFFFAOYSA-N 3-benzyl-1,5-didiazoniopenta-1,4-diene-2,4-diolate Chemical compound [N-]=[N+]=CC(=O)C(C(=O)C=[N+]=[N-])CC1=CC=CC=C1 BIGBDMFRWJRLGJ-UHFFFAOYSA-N 0.000 description 1
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
NLPWSMKACWGINL-UHFFFAOYSA-N 4-azido-2-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(N=[N+]=[N-])C=C1O NLPWSMKACWGINL-UHFFFAOYSA-N 0.000 description 1
QRXMUCSWCMTJGU-UHFFFAOYSA-N 5-bromo-4-chloro-3-indolyl phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP(O)(=O)O)=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-N 0.000 description 1
108010066676 Abrin Proteins 0.000 description 1
208000016557 Acute basophilic leukemia Diseases 0.000 description 1
229930024421 Adenine Natural products 0.000 description 1
GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
208000004804 Adenomatous Polyps Diseases 0.000 description 1
VJVQKGYHIZPSNS-FXQIFTODSA-N Ala-Ser-Arg Chemical compound C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCCN=C(N)N VJVQKGYHIZPSNS-FXQIFTODSA-N 0.000 description 1
201000003076 Angiosarcoma Diseases 0.000 description 1
108020005544 Antisense RNA Proteins 0.000 description 1
241000203069 Archaea Species 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
HCAUEJAQCXVQQM-ACZMJKKPSA-N Asn-Glu-Asp Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O HCAUEJAQCXVQQM-ACZMJKKPSA-N 0.000 description 1
206010065869 Astrocytoma, low grade Diseases 0.000 description 1
102100022717 Atypical chemokine receptor 1 Human genes 0.000 description 1
108020004513 Bacterial RNA Proteins 0.000 description 1
206010004146 Basal cell carcinoma Diseases 0.000 description 1
208000035821 Benign schwannoma Diseases 0.000 description 1
239000005711 Benzoic acid Substances 0.000 description 1
102100031403 Beta-1,3-N-acetylglucosaminyltransferase lunatic fringe Human genes 0.000 description 1
DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
208000007690 Brenner tumor Diseases 0.000 description 1
206010073258 Brenner tumour Diseases 0.000 description 1
208000003170 Bronchiolo-Alveolar Adenocarcinoma Diseases 0.000 description 1
125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
239000002126 C01EB10 - Adenosine Substances 0.000 description 1
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
241000222122 Candida albicans Species 0.000 description 1
241000283707 Capra Species 0.000 description 1
206010007275 Carcinoid tumour Diseases 0.000 description 1
241000700198 Cavia Species 0.000 description 1
108091006146 Channels Proteins 0.000 description 1
206010008583 Chloroma Diseases 0.000 description 1
201000009047 Chordoma Diseases 0.000 description 1
208000006332 Choriocarcinoma Diseases 0.000 description 1
206010008805 Chromosomal abnormalities Diseases 0.000 description 1
206010061764 Chromosomal deletion Diseases 0.000 description 1
208000031404 Chromosome Aberrations Diseases 0.000 description 1
WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
108091035707 Consensus sequence Proteins 0.000 description 1
RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
108700032819 Croton tiglium crotin II Proteins 0.000 description 1
101710095468 Cyclase Proteins 0.000 description 1
ZGERHCJBLPQPGV-ACZMJKKPSA-N Cys-Ser-Gln Chemical compound C(CC(=O)N)[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CS)N ZGERHCJBLPQPGV-ACZMJKKPSA-N 0.000 description 1
IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
GUBGYTABKSRVRQ-PICCSMPSSA-N D-Maltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
108010092160 Dactinomycin Proteins 0.000 description 1
CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 1
241000255601 Drosophila melanogaster Species 0.000 description 1
206010013710 Drug interaction Diseases 0.000 description 1
208000037162 Ductal Breast Carcinoma Diseases 0.000 description 1
208000007033 Dysgerminoma Diseases 0.000 description 1
201000009051 Embryonal Carcinoma Diseases 0.000 description 1
101710202200 Endolysin A Proteins 0.000 description 1
102000004533 Endonucleases Human genes 0.000 description 1
108010042407 Endonucleases Proteins 0.000 description 1
102100030013 Endoribonuclease Human genes 0.000 description 1
101710199605 Endoribonuclease Proteins 0.000 description 1
206010014958 Eosinophilic leukaemia Diseases 0.000 description 1
206010014967 Ependymoma Diseases 0.000 description 1
241000283086 Equidae Species 0.000 description 1
208000031637 Erythroblastic Acute Leukemia Diseases 0.000 description 1
208000036566 Erythroleukaemia Diseases 0.000 description 1
108060002716 Exonuclease Proteins 0.000 description 1
101710082714 Exotoxin A Proteins 0.000 description 1
102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
201000006107 Familial adenomatous polyposis Diseases 0.000 description 1
206010053717 Fibrous histiocytoma Diseases 0.000 description 1
241000192125 Firmicutes Species 0.000 description 1
BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
208000004463 Follicular Adenocarcinoma Diseases 0.000 description 1
241000233866 Fungi Species 0.000 description 1
102100021241 G protein-activated inward rectifier potassium channel 3 Human genes 0.000 description 1
206010017708 Ganglioneuroblastoma Diseases 0.000 description 1
208000008999 Giant Cell Carcinoma Diseases 0.000 description 1
208000002966 Giant Cell Tumor of Bone Diseases 0.000 description 1
FTIJVMLAGRAYMJ-MNXVOIDGSA-N Gln-Ile-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](N)CCC(N)=O FTIJVMLAGRAYMJ-MNXVOIDGSA-N 0.000 description 1
CBEUFCJRFNZMCU-SRVKXCTJSA-N Glu-Met-Leu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(C)C)C(O)=O CBEUFCJRFNZMCU-SRVKXCTJSA-N 0.000 description 1
102000042092 Glucose transporter family Human genes 0.000 description 1
108091052347 Glucose transporter family Proteins 0.000 description 1
SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
ZZJVYSAQQMDIRD-UWVGGRQHSA-N Gly-Pro-His Chemical compound NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1cnc[nH]1)C(O)=O ZZJVYSAQQMDIRD-UWVGGRQHSA-N 0.000 description 1
244000068988 Glycine max Species 0.000 description 1
235000010469 Glycine max Nutrition 0.000 description 1
208000005234 Granulosa Cell Tumor Diseases 0.000 description 1
HVLSXIKZNLPZJJ-TXZCQADKSA-N HA peptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 HVLSXIKZNLPZJJ-TXZCQADKSA-N 0.000 description 1
208000002125 Hemangioendothelioma Diseases 0.000 description 1
208000006050 Hemangiopericytoma Diseases 0.000 description 1
208000001258 Hemangiosarcoma Diseases 0.000 description 1
229920000209 Hexadimethrine bromide Polymers 0.000 description 1
RXVOMIADLXPJGW-GUBZILKMSA-N His-Asp-Glu Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O RXVOMIADLXPJGW-GUBZILKMSA-N 0.000 description 1
LYCVKHSJGDMDLM-LURJTMIESA-N His-Gly Chemical compound OC(=O)CNC(=O)[C@@H](N)CC1=CN=CN1 LYCVKHSJGDMDLM-LURJTMIESA-N 0.000 description 1
208000002291 Histiocytic Sarcoma Diseases 0.000 description 1
208000021519 Hodgkin lymphoma Diseases 0.000 description 1
101000678879 Homo sapiens Atypical chemokine receptor 1 Proteins 0.000 description 1
101001130526 Homo sapiens Beta-1,3-N-acetylglucosaminyltransferase lunatic fringe Proteins 0.000 description 1
101000614721 Homo sapiens G protein-activated inward rectifier potassium channel 3 Proteins 0.000 description 1
101001123304 Homo sapiens PR domain-containing protein 11 Proteins 0.000 description 1
101000611251 Homo sapiens Serine/threonine-protein phosphatase 2B catalytic subunit gamma isoform Proteins 0.000 description 1
101000908580 Homo sapiens Spliceosome RNA helicase DDX39B Proteins 0.000 description 1
101001074035 Homo sapiens Zinc finger protein GLI2 Proteins 0.000 description 1
108010001336 Horseradish Peroxidase Proteins 0.000 description 1
108090000144 Human Proteins Proteins 0.000 description 1
102000003839 Human Proteins Human genes 0.000 description 1
PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
206010048643 Hypereosinophilic syndrome Diseases 0.000 description 1
108010050332 IQ motif containing GTPase activating protein 1 Proteins 0.000 description 1
RENBRDSDKPSRIH-HJWJTTGWSA-N Ile-Phe-Met Chemical compound N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCSC)C(=O)O RENBRDSDKPSRIH-HJWJTTGWSA-N 0.000 description 1
102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 1
108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 1
102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
108700005091 Immunoglobulin Genes Proteins 0.000 description 1
102000016844 Immunoglobulin-like domains Human genes 0.000 description 1
108050006430 Immunoglobulin-like domains Proteins 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
108010001127 Insulin Receptor Proteins 0.000 description 1
102100036721 Insulin receptor Human genes 0.000 description 1
102000000589 Interleukin-1 Human genes 0.000 description 1
108010002352 Interleukin-1 Proteins 0.000 description 1
102000019223 Interleukin-1 receptor Human genes 0.000 description 1
108050006617 Interleukin-1 receptor Proteins 0.000 description 1
102000000588 Interleukin-2 Human genes 0.000 description 1
108010002350 Interleukin-2 Proteins 0.000 description 1
102000010789 Interleukin-2 Receptors Human genes 0.000 description 1
108010038453 Interleukin-2 Receptors Proteins 0.000 description 1
201000008869 Juxtacortical Osteosarcoma Diseases 0.000 description 1
244000285963 Kluyveromyces fragilis Species 0.000 description 1
235000014663 Kluyveromyces fragilis Nutrition 0.000 description 1
241001138401 Kluyveromyces lactis Species 0.000 description 1
XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 1
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
JTTHKOPSMAVJFE-VIFPVBQESA-N L-homophenylalanine Chemical compound OC(=O)[C@@H](N)CCC1=CC=CC=C1 JTTHKOPSMAVJFE-VIFPVBQESA-N 0.000 description 1
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
TYYLDKGBCJGJGW-UHFFFAOYSA-N L-tryptophan-L-tyrosine Natural products C=1NC2=CC=CC=C2C=1CC(N)C(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 TYYLDKGBCJGJGW-UHFFFAOYSA-N 0.000 description 1
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
108010001831 LDL receptors Proteins 0.000 description 1
102000000853 LDL receptors Human genes 0.000 description 1
101150112373 LFNG gene Proteins 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
208000018142 Leiomyosarcoma Diseases 0.000 description 1
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
201000004462 Leydig Cell Tumor Diseases 0.000 description 1
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
208000000265 Lobular Carcinoma Diseases 0.000 description 1
DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
YKIRNDPUWONXQN-GUBZILKMSA-N Lys-Asn-Gln Chemical compound C(CCN)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N YKIRNDPUWONXQN-GUBZILKMSA-N 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
208000035771 Malignant Sertoli-Leydig cell tumor of the ovary Diseases 0.000 description 1
208000007054 Medullary Carcinoma Diseases 0.000 description 1
102000018697 Membrane Proteins Human genes 0.000 description 1
108010052285 Membrane Proteins Proteins 0.000 description 1
208000002030 Merkel cell carcinoma Diseases 0.000 description 1
201000009574 Mesenchymal Chondrosarcoma Diseases 0.000 description 1
206010054949 Metaplasia Diseases 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
241000713333 Mouse mammary tumor virus Species 0.000 description 1
206010057269 Mucoepidermoid carcinoma Diseases 0.000 description 1
208000010357 Mullerian Mixed Tumor Diseases 0.000 description 1
101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical class ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 1
229930193140 Neomycin Natural products 0.000 description 1
108010025020 Nerve Growth Factor Proteins 0.000 description 1
102000007072 Nerve Growth Factors Human genes 0.000 description 1
206010029260 Neuroblastoma Diseases 0.000 description 1
241000221960 Neurospora Species 0.000 description 1
GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
108010077850 Nuclear Localization Signals Proteins 0.000 description 1
102100023421 Nuclear receptor ROR-gamma Human genes 0.000 description 1
108091007494 Nucleic acid- binding domains Proteins 0.000 description 1
230000004989 O-glycosylation Effects 0.000 description 1
208000007871 Odontogenic Tumors Diseases 0.000 description 1
241000320412 Ogataea angusta Species 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
206010073261 Ovarian theca cell tumour Diseases 0.000 description 1
102100028957 PR domain-containing protein 11 Human genes 0.000 description 1
206010061332 Paraganglion neoplasm Diseases 0.000 description 1
241001494479 Pecora Species 0.000 description 1
108010067902 Peptide Library Proteins 0.000 description 1
108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
241000235648 Pichia Species 0.000 description 1
208000009077 Pigmented Nevus Diseases 0.000 description 1
208000019262 Pilomatrix carcinoma Diseases 0.000 description 1
208000007641 Pinealoma Diseases 0.000 description 1
241000276498 Pollachius virens Species 0.000 description 1
239000004743 Polypropylene Substances 0.000 description 1
241000288906 Primates Species 0.000 description 1
102100033237 Pro-epidermal growth factor Human genes 0.000 description 1
206010060862 Prostate cancer Diseases 0.000 description 1
208000000236 Prostatic Neoplasms Diseases 0.000 description 1
238000012341 Quantitative reverse-transcriptase PCR Methods 0.000 description 1
IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
108020004518 RNA Probes Proteins 0.000 description 1
239000003391 RNA probe Substances 0.000 description 1
108020004511 Recombinant DNA Proteins 0.000 description 1
201000000582 Retinoblastoma Diseases 0.000 description 1
102000006382 Ribonucleases Human genes 0.000 description 1
108010083644 Ribonucleases Proteins 0.000 description 1
108091028664 Ribonucleotide Proteins 0.000 description 1
108010039491 Ricin Proteins 0.000 description 1
102000000395 SH3 domains Human genes 0.000 description 1
108050008861 SH3 domains Proteins 0.000 description 1
241000235346 Schizosaccharomyces Species 0.000 description 1
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
101710113029 Serine/threonine-protein kinase Proteins 0.000 description 1
102100040320 Serine/threonine-protein phosphatase 2B catalytic subunit gamma isoform Human genes 0.000 description 1
208000000097 Sertoli-Leydig cell tumor Diseases 0.000 description 1
108010071390 Serum Albumin Proteins 0.000 description 1
102000007562 Serum Albumin Human genes 0.000 description 1
208000003252 Signet Ring Cell Carcinoma Diseases 0.000 description 1
XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
208000009574 Skin Appendage Carcinoma Diseases 0.000 description 1
108010017622 Somatomedin Receptors Proteins 0.000 description 1
102000004584 Somatomedin Receptors Human genes 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
241000282887 Suidae Species 0.000 description 1
101000930762 Sulfolobus acidocaldarius (strain ATCC 33909 / DSM 639 / JCM 8929 / NBRC 15157 / NCIMB 11770) Signal recognition particle receptor FtsY Proteins 0.000 description 1
206010042553 Superficial spreading melanoma stage unspecified Diseases 0.000 description 1
108091008874 T cell receptors Proteins 0.000 description 1
230000005867 T cell response Effects 0.000 description 1
102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
239000004098 Tetracycline Substances 0.000 description 1
GQPQJNMVELPZNQ-GBALPHGKSA-N Thr-Ser-Trp Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)N)O GQPQJNMVELPZNQ-GBALPHGKSA-N 0.000 description 1
201000009365 Thymic carcinoma Diseases 0.000 description 1
108010034949 Thyroglobulin Proteins 0.000 description 1
102000009843 Thyroglobulin Human genes 0.000 description 1
101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
108010033576 Transferrin Receptors Proteins 0.000 description 1
102000007238 Transferrin Receptors Human genes 0.000 description 1
HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
229940122618 Trypsin inhibitor Drugs 0.000 description 1
101710162629 Trypsin inhibitor Proteins 0.000 description 1
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
102000004243 Tubulin Human genes 0.000 description 1
108090000704 Tubulin Proteins 0.000 description 1
108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
102100040247 Tumor necrosis factor Human genes 0.000 description 1
LUMQYLVYUIRHHU-YJRXYDGGSA-N Tyr-Ser-Thr Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(O)=O LUMQYLVYUIRHHU-YJRXYDGGSA-N 0.000 description 1
FZADUTOCSFDBRV-RNXOBYDBSA-N Tyr-Tyr-Trp Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)C1=CC=C(O)C=C1 FZADUTOCSFDBRV-RNXOBYDBSA-N 0.000 description 1
GVJUTBOZZBTBIG-AVGNSLFASA-N Val-Lys-Arg Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N GVJUTBOZZBTBIG-AVGNSLFASA-N 0.000 description 1
241000251539 Vertebrata <Metazoa> Species 0.000 description 1
JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
208000036142 Viral infection Diseases 0.000 description 1
208000008383 Wilms tumor Diseases 0.000 description 1
206010052428 Wound Diseases 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
241000235015 Yarrowia lipolytica Species 0.000 description 1
240000008042 Zea mays Species 0.000 description 1
235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
235000002017 Zea mays subsp mays Nutrition 0.000 description 1
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
102100026568 Zinc finger and SCAN domain-containing protein 2 Human genes 0.000 description 1
101710119061 Zinc finger and SCAN domain-containing protein 2 Proteins 0.000 description 1
102100035558 Zinc finger protein GLI2 Human genes 0.000 description 1
230000001594 aberrant effect Effects 0.000 description 1
230000021736 acetylation Effects 0.000 description 1
238000006640 acetylation reaction Methods 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
208000006336 acinar cell carcinoma Diseases 0.000 description 1
229920006397 acrylic thermoplastic Polymers 0.000 description 1
RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
230000036982 action potential Effects 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
239000012190 activator Substances 0.000 description 1
208000021841 acute erythroid leukemia Diseases 0.000 description 1
230000010933 acylation Effects 0.000 description 1
238000005917 acylation reaction Methods 0.000 description 1
239000000654 additive Substances 0.000 description 1
229960000643 adenine Drugs 0.000 description 1
208000002517 adenoid cystic carcinoma Diseases 0.000 description 1
229960005305 adenosine Drugs 0.000 description 1
201000008395 adenosquamous carcinoma Diseases 0.000 description 1
108060000200 adenylate cyclase Proteins 0.000 description 1
102000030621 adenylate cyclase Human genes 0.000 description 1
208000020990 adrenal cortex carcinoma Diseases 0.000 description 1
208000007128 adrenocortical carcinoma Diseases 0.000 description 1
238000001261 affinity purification Methods 0.000 description 1
230000032683 aging Effects 0.000 description 1
125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 1
PPQRONHOSHZGFQ-LMVFSUKVSA-N aldehydo-D-ribose 5-phosphate Chemical group OP(=O)(O)OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PPQRONHOSHZGFQ-LMVFSUKVSA-N 0.000 description 1
125000000217 alkyl group Chemical group 0.000 description 1
230000029936 alkylation Effects 0.000 description 1
238000005804 alkylation reaction Methods 0.000 description 1
HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
206010065867 alveolar rhabdomyosarcoma Diseases 0.000 description 1
208000006431 amelanotic melanoma Diseases 0.000 description 1
208000010029 ameloblastoma Diseases 0.000 description 1
230000009435 amidation Effects 0.000 description 1
238000007112 amidation reaction Methods 0.000 description 1
229960003896 aminopterin Drugs 0.000 description 1
229960000723 ampicillin Drugs 0.000 description 1
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
210000002255 anal canal Anatomy 0.000 description 1
210000004102 animal cell Anatomy 0.000 description 1
239000010775 animal oil Substances 0.000 description 1
230000005875 antibody response Effects 0.000 description 1
210000000436 anus Anatomy 0.000 description 1
201000007436 apocrine adenocarcinoma Diseases 0.000 description 1
239000012736 aqueous medium Substances 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
108010062796 arginyllysine Proteins 0.000 description 1
125000003118 aryl group Chemical group 0.000 description 1
125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 1
201000005476 astroblastoma Diseases 0.000 description 1
230000003305 autocrine Effects 0.000 description 1
230000035578 autophosphorylation Effects 0.000 description 1
239000012752 auxiliary agent Substances 0.000 description 1
201000007551 basophilic adenocarcinoma Diseases 0.000 description 1
239000011324 bead Substances 0.000 description 1
230000008901 benefit Effects 0.000 description 1
208000001119 benign fibrous histiocytoma Diseases 0.000 description 1
235000010233 benzoic acid Nutrition 0.000 description 1
102000005936 beta-Galactosidase Human genes 0.000 description 1
108010005774 beta-Galactosidase Proteins 0.000 description 1
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
230000001851 biosynthetic effect Effects 0.000 description 1
230000006696 biosynthetic metabolic pathway Effects 0.000 description 1
238000009534 blood test Methods 0.000 description 1
208000007047 blue nevus Diseases 0.000 description 1
230000037396 body weight Effects 0.000 description 1
210000000988 bone and bone Anatomy 0.000 description 1
201000011143 bone giant cell tumor Diseases 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
210000000133 brain stem Anatomy 0.000 description 1
210000000481 breast Anatomy 0.000 description 1
201000003714 breast lobular carcinoma Diseases 0.000 description 1
201000011054 breast malignant phyllodes tumor Diseases 0.000 description 1
210000000621 bronchi Anatomy 0.000 description 1
KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
210000004899 c-terminal region Anatomy 0.000 description 1
239000001110 calcium chloride Substances 0.000 description 1
229910001628 calcium chloride Inorganic materials 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
208000035269 cancer or benign tumor Diseases 0.000 description 1
230000000711 cancerogenic effect Effects 0.000 description 1
229940095731 candida albicans Drugs 0.000 description 1
239000002775 capsule Substances 0.000 description 1
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
231100000315 carcinogenic Toxicity 0.000 description 1
208000002458 carcinoid tumor Diseases 0.000 description 1
239000000969 carrier Substances 0.000 description 1
239000005018 casein Substances 0.000 description 1
BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
235000021240 caseins Nutrition 0.000 description 1
230000021164 cell adhesion Effects 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
230000033366 cell cycle process Effects 0.000 description 1
230000003915 cell function Effects 0.000 description 1
230000004663 cell proliferation Effects 0.000 description 1
230000033077 cellular process Effects 0.000 description 1
230000036755 cellular response Effects 0.000 description 1
230000002490 cerebral effect Effects 0.000 description 1
201000002891 ceruminous adenocarcinoma Diseases 0.000 description 1
208000024188 ceruminous carcinoma Diseases 0.000 description 1
210000003679 cervix uteri Anatomy 0.000 description 1
230000003196 chaotropic effect Effects 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
239000002738 chelating agent Substances 0.000 description 1
238000010382 chemical cross-linking Methods 0.000 description 1
125000003636 chemical group Chemical group 0.000 description 1
238000007385 chemical modification Methods 0.000 description 1
229960005091 chloramphenicol Drugs 0.000 description 1
WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
208000006990 cholangiocarcinoma Diseases 0.000 description 1
201000005217 chondroblastoma Diseases 0.000 description 1
238000011098 chromatofocusing Methods 0.000 description 1
201000010240 chromophobe renal cell carcinoma Diseases 0.000 description 1
208000021668 chronic eosinophilic leukemia Diseases 0.000 description 1
235000013985 cinnamic acid Nutrition 0.000 description 1
229930016911 cinnamic acid Natural products 0.000 description 1
DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
229960004316 cisplatin Drugs 0.000 description 1
235000015165 citric acid Nutrition 0.000 description 1
229960002173 citrulline Drugs 0.000 description 1
235000013477 citrulline Nutrition 0.000 description 1
208000029664 classic familial adenomatous polyposis Diseases 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
210000001072 colon Anatomy 0.000 description 1
239000003086 colorant Substances 0.000 description 1
208000011588 combined hepatocellular carcinoma and cholangiocarcinoma Diseases 0.000 description 1
238000012875 competitive assay Methods 0.000 description 1
230000009137 competitive binding Effects 0.000 description 1
239000003184 complementary RNA Substances 0.000 description 1
230000021615 conjugation Effects 0.000 description 1
239000000470 constituent Substances 0.000 description 1
229920001577 copolymer Polymers 0.000 description 1
229910052802 copper Inorganic materials 0.000 description 1
239000010949 copper Substances 0.000 description 1
235000005822 corn Nutrition 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
239000003431 cross linking reagent Substances 0.000 description 1
238000012258 culturing Methods 0.000 description 1
208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
230000001351 cycling effect Effects 0.000 description 1
208000002445 cystadenocarcinoma Diseases 0.000 description 1
210000000805 cytoplasm Anatomy 0.000 description 1
229940104302 cytosine Drugs 0.000 description 1
231100000433 cytotoxic Toxicity 0.000 description 1
210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
230000001472 cytotoxic effect Effects 0.000 description 1
231100000135 cytotoxicity Toxicity 0.000 description 1
230000003013 cytotoxicity Effects 0.000 description 1
229960000640 dactinomycin Drugs 0.000 description 1
230000006240 deamidation Effects 0.000 description 1
230000002950 deficient Effects 0.000 description 1
230000022811 deglycosylation Effects 0.000 description 1
230000002939 deleterious effect Effects 0.000 description 1
108010005905 delta-hGHR Proteins 0.000 description 1
238000001212 derivatisation Methods 0.000 description 1
230000000368 destabilizing effect Effects 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
230000037213 diet Effects 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
230000001079 digestive effect Effects 0.000 description 1
210000002249 digestive system Anatomy 0.000 description 1
LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 1
229960005156 digoxin Drugs 0.000 description 1
LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 description 1
230000003292 diminished effect Effects 0.000 description 1
NAGJZTKCGNOGPW-UHFFFAOYSA-K dioxido-sulfanylidene-sulfido-$l^{5}-phosphane Chemical compound [O-]P([O-])([S-])=S NAGJZTKCGNOGPW-UHFFFAOYSA-K 0.000 description 1
206010013023 diphtheria Diseases 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
238000009826 distribution Methods 0.000 description 1
PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
238000009510 drug design Methods 0.000 description 1
239000003596 drug target Substances 0.000 description 1
210000000959 ear middle Anatomy 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
238000002337 electrophoretic mobility shift assay Methods 0.000 description 1
201000009409 embryonal rhabdomyosarcoma Diseases 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
238000005538 encapsulation Methods 0.000 description 1
210000000750 endocrine system Anatomy 0.000 description 1
230000012202 endocytosis Effects 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
108010028531 enomycin Proteins 0.000 description 1
239000002532 enzyme inhibitor Substances 0.000 description 1
229940125532 enzyme inhibitor Drugs 0.000 description 1
210000002919 epithelial cell Anatomy 0.000 description 1
201000010877 epithelioid cell melanoma Diseases 0.000 description 1
229960003276 erythromycin Drugs 0.000 description 1
210000003238 esophagus Anatomy 0.000 description 1
230000032050 esterification Effects 0.000 description 1
238000005886 esterification reaction Methods 0.000 description 1
CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
210000003527 eukaryotic cell Anatomy 0.000 description 1
102000013165 exonuclease Human genes 0.000 description 1
210000002744 extracellular matrix Anatomy 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
210000004996 female reproductive system Anatomy 0.000 description 1
201000001169 fibrillary astrocytoma Diseases 0.000 description 1
201000008825 fibrosarcoma of bone Diseases 0.000 description 1
239000000945 filler Substances 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
230000003325 follicular Effects 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
239000001530 fumaric acid Substances 0.000 description 1
235000011087 fumaric acid Nutrition 0.000 description 1
238000002825 functional assay Methods 0.000 description 1
210000000232 gallbladder Anatomy 0.000 description 1
208000015419 gastrin-producing neuroendocrine tumor Diseases 0.000 description 1
201000000052 gastrinoma Diseases 0.000 description 1
238000001502 gel electrophoresis Methods 0.000 description 1
238000003209 gene knockout Methods 0.000 description 1
238000010363 gene targeting Methods 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
210000004602 germ cell Anatomy 0.000 description 1
208000005017 glioblastoma Diseases 0.000 description 1
201000002264 glomangiosarcoma Diseases 0.000 description 1
125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 1
108010042598 glutamyl-aspartyl-glycine Proteins 0.000 description 1
229930182470 glycoside Natural products 0.000 description 1
150000002338 glycosides Chemical class 0.000 description 1
201000007574 granular cell carcinoma Diseases 0.000 description 1
239000008187 granular material Substances 0.000 description 1
201000009277 hairy cell leukemia Diseases 0.000 description 1
230000036541 health Effects 0.000 description 1
210000002443 helper t lymphocyte Anatomy 0.000 description 1
208000006359 hepatoblastoma Diseases 0.000 description 1
206010073071 hepatocellular carcinoma Diseases 0.000 description 1
231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
125000004404 heteroalkyl group Chemical group 0.000 description 1
125000000623 heterocyclic group Chemical group 0.000 description 1
208000029824 high grade glioma Diseases 0.000 description 1
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
239000005556 hormone Substances 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
125000001165 hydrophobic group Chemical group 0.000 description 1
230000033444 hydroxylation Effects 0.000 description 1
238000005805 hydroxylation reaction Methods 0.000 description 1
229960002591 hydroxyproline Drugs 0.000 description 1
210000003026 hypopharynx Anatomy 0.000 description 1
150000002463 imidates Chemical class 0.000 description 1
125000001841 imino group Chemical group [H]N=* 0.000 description 1
230000003100 immobilizing effect Effects 0.000 description 1
230000009851 immunogenic response Effects 0.000 description 1
230000016784 immunoglobulin production Effects 0.000 description 1
238000001114 immunoprecipitation Methods 0.000 description 1
230000001024 immunotherapeutic effect Effects 0.000 description 1
238000007901 in situ hybridization Methods 0.000 description 1
238000012750 in vivo screening Methods 0.000 description 1
230000000415 inactivating effect Effects 0.000 description 1
230000002779 inactivation Effects 0.000 description 1
239000000411 inducer Substances 0.000 description 1
230000002757 inflammatory effect Effects 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
150000007529 inorganic bases Chemical class 0.000 description 1
238000007689 inspection Methods 0.000 description 1
230000008611 intercellular interaction Effects 0.000 description 1
102000002467 interleukin receptors Human genes 0.000 description 1
108010093036 interleukin receptors Proteins 0.000 description 1
208000028774 intestinal disease Diseases 0.000 description 1
210000003228 intrahepatic bile duct Anatomy 0.000 description 1
239000007928 intraperitoneal injection Substances 0.000 description 1
206010073096 invasive lobular breast carcinoma Diseases 0.000 description 1
238000005342 ion exchange Methods 0.000 description 1
239000003456 ion exchange resin Substances 0.000 description 1
229920003303 ion-exchange polymer Polymers 0.000 description 1
229910052742 iron Inorganic materials 0.000 description 1
238000001155 isoelectric focusing Methods 0.000 description 1
125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 description 1
JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
150000002540 isothiocyanates Chemical class 0.000 description 1
230000000155 isotopic effect Effects 0.000 description 1
229950003188 isovaleryl diethylamide Drugs 0.000 description 1
229960000318 kanamycin Drugs 0.000 description 1
229930027917 kanamycin Natural products 0.000 description 1
SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
229930182823 kanamycin A Natural products 0.000 description 1
108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 1
208000022013 kidney Wilms tumor Diseases 0.000 description 1
239000008101 lactose Substances 0.000 description 1
210000000867 larynx Anatomy 0.000 description 1
102000005861 leptin receptors Human genes 0.000 description 1
108010019813 leptin receptors Proteins 0.000 description 1
125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
210000004901 leucine-rich repeat Anatomy 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
125000003473 lipid group Chemical group 0.000 description 1
206010024627 liposarcoma Diseases 0.000 description 1
239000002502 liposome Substances 0.000 description 1
229910052744 lithium Inorganic materials 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
230000007774 longterm Effects 0.000 description 1
239000006210 lotion Substances 0.000 description 1
231100000053 low toxicity Toxicity 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
201000000014 lung giant cell carcinoma Diseases 0.000 description 1
210000001165 lymph node Anatomy 0.000 description 1
208000012804 lymphangiosarcoma Diseases 0.000 description 1
230000001926 lymphatic effect Effects 0.000 description 1
230000000527 lymphocytic effect Effects 0.000 description 1
201000010953 lymphoepithelioma-like carcinoma Diseases 0.000 description 1
208000025036 lymphosarcoma Diseases 0.000 description 1
125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
239000012139 lysis buffer Substances 0.000 description 1
230000002101 lytic effect Effects 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
159000000003 magnesium salts Chemical class 0.000 description 1
239000006249 magnetic particle Substances 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
210000004995 male reproductive system Anatomy 0.000 description 1
208000018013 malignant glomus tumor Diseases 0.000 description 1
201000004102 malignant granular cell myoblastoma Diseases 0.000 description 1
201000006812 malignant histiocytosis Diseases 0.000 description 1
206010061526 malignant mesenchymoma Diseases 0.000 description 1
201000009020 malignant peripheral nerve sheath tumor Diseases 0.000 description 1
201000002338 malignant struma ovarii Diseases 0.000 description 1
201000000289 malignant teratoma Diseases 0.000 description 1
229960002510 mandelic acid Drugs 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
238000004949 mass spectrometry Methods 0.000 description 1
208000000516 mast-cell leukemia Diseases 0.000 description 1
201000008749 mast-cell sarcoma Diseases 0.000 description 1
210000001370 mediastinum Anatomy 0.000 description 1
239000002609 medium Substances 0.000 description 1
208000023356 medullary thyroid gland carcinoma Diseases 0.000 description 1
230000008018 melting Effects 0.000 description 1
206010027191 meningioma Diseases 0.000 description 1
210000000713 mesentery Anatomy 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
150000002739 metals Chemical class 0.000 description 1
230000015689 metaplastic ossification Effects 0.000 description 1
229940098779 methanesulfonic acid Drugs 0.000 description 1
229960000485 methotrexate Drugs 0.000 description 1
YCXSYMVGMXQYNT-UHFFFAOYSA-N methyl 3-[(4-azidophenyl)disulfanyl]propanimidate Chemical compound COC(=N)CCSSC1=CC=C(N=[N+]=[N-])C=C1 YCXSYMVGMXQYNT-UHFFFAOYSA-N 0.000 description 1
WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
230000011987 methylation Effects 0.000 description 1
238000007069 methylation reaction Methods 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
238000000520 microinjection Methods 0.000 description 1
230000003278 mimic effect Effects 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
239000003226 mitogen Substances 0.000 description 1
201000010225 mixed cell type cancer Diseases 0.000 description 1
208000029638 mixed neoplasm Diseases 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
229940035032 monophosphoryl lipid a Drugs 0.000 description 1
201000010879 mucinous adenocarcinoma Diseases 0.000 description 1
208000010492 mucinous cystadenocarcinoma Diseases 0.000 description 1
238000002887 multiple sequence alignment Methods 0.000 description 1
230000000869 mutational effect Effects 0.000 description 1
201000005962 mycosis fungoides Diseases 0.000 description 1
201000005987 myeloid sarcoma Diseases 0.000 description 1
208000001611 myxosarcoma Diseases 0.000 description 1
229940022007 naked DNA vaccine Drugs 0.000 description 1
210000003928 nasal cavity Anatomy 0.000 description 1
208000014761 nasopharyngeal type undifferentiated carcinoma Diseases 0.000 description 1
210000001989 nasopharynx Anatomy 0.000 description 1
229960004927 neomycin Drugs 0.000 description 1
201000008026 nephroblastoma Diseases 0.000 description 1
208000007538 neurilemmoma Diseases 0.000 description 1
230000004770 neurodegeneration Effects 0.000 description 1
208000015122 neurodegenerative disease Diseases 0.000 description 1
208000027831 neuroepithelial neoplasm Diseases 0.000 description 1
208000029974 neurofibrosarcoma Diseases 0.000 description 1
230000001272 neurogenic effect Effects 0.000 description 1
239000003900 neurotrophic factor Substances 0.000 description 1
239000002547 new drug Substances 0.000 description 1
229910017604 nitric acid Inorganic materials 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
238000007826 nucleic acid assay Methods 0.000 description 1
208000027825 odontogenic neoplasm Diseases 0.000 description 1
235000014593 oils and fats Nutrition 0.000 description 1
239000002674 ointment Substances 0.000 description 1
210000002747 omentum Anatomy 0.000 description 1
231100000590 oncogenic Toxicity 0.000 description 1
230000002246 oncogenic effect Effects 0.000 description 1
238000011275 oncology therapy Methods 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
210000003463 organelle Anatomy 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
210000003300 oropharynx Anatomy 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
201000008968 osteosarcoma Diseases 0.000 description 1
230000002611 ovarian Effects 0.000 description 1
208000012221 ovarian Sertoli-Leydig cell tumor Diseases 0.000 description 1
210000001672 ovary Anatomy 0.000 description 1
235000006408 oxalic acid Nutrition 0.000 description 1
125000004043 oxo group Chemical group O=* 0.000 description 1
210000002741 palatine tonsil Anatomy 0.000 description 1
210000000496 pancreas Anatomy 0.000 description 1
FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
208000004019 papillary adenocarcinoma Diseases 0.000 description 1
201000010198 papillary carcinoma Diseases 0.000 description 1
201000010210 papillary cystadenocarcinoma Diseases 0.000 description 1
208000024641 papillary serous cystadenocarcinoma Diseases 0.000 description 1
201000001494 papillary transitional carcinoma Diseases 0.000 description 1
208000031101 papillary transitional cell carcinoma Diseases 0.000 description 1
230000003076 paracrine Effects 0.000 description 1
208000007312 paraganglioma Diseases 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
239000002245 particle Substances 0.000 description 1
230000001717 pathogenic effect Effects 0.000 description 1
230000037361 pathway Effects 0.000 description 1
230000035515 penetration Effects 0.000 description 1
210000003899 penis Anatomy 0.000 description 1
239000000816 peptidomimetic Substances 0.000 description 1
210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
210000001322 periplasm Anatomy 0.000 description 1
210000004303 peritoneum Anatomy 0.000 description 1
102000013415 peroxidase activity proteins Human genes 0.000 description 1
108040007629 peroxidase activity proteins Proteins 0.000 description 1
238000002823 phage display Methods 0.000 description 1
239000012071 phase Substances 0.000 description 1
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
125000000405 phenylalanyl group Chemical group 0.000 description 1
208000028591 pheochromocytoma Diseases 0.000 description 1
PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical compound NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 description 1
238000003566 phosphorylation assay Methods 0.000 description 1
230000004962 physiological condition Effects 0.000 description 1
230000035479 physiological effects, processes and functions Effects 0.000 description 1
230000035790 physiological processes and functions Effects 0.000 description 1
239000006187 pill Substances 0.000 description 1
208000024724 pineal body neoplasm Diseases 0.000 description 1
201000004123 pineal gland cancer Diseases 0.000 description 1
208000021857 pituitary gland basophilic carcinoma Diseases 0.000 description 1
208000031223 plasma cell leukemia Diseases 0.000 description 1
239000013612 plasmid Substances 0.000 description 1
210000004224 pleura Anatomy 0.000 description 1
229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
229920001748 polybutylene Polymers 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
238000003752 polymerase chain reaction Methods 0.000 description 1
229920001155 polypropylene Polymers 0.000 description 1
229920001451 polypropylene glycol Polymers 0.000 description 1
229920002635 polyurethane Polymers 0.000 description 1
239000004814 polyurethane Substances 0.000 description 1
239000013641 positive control Substances 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
239000002243 precursor Substances 0.000 description 1
150000003141 primary amines Chemical class 0.000 description 1
230000008569 process Effects 0.000 description 1
150000003148 prolines Chemical class 0.000 description 1
235000019260 propionic acid Nutrition 0.000 description 1
210000002307 prostate Anatomy 0.000 description 1
210000005267 prostate cell Anatomy 0.000 description 1
238000001742 protein purification Methods 0.000 description 1
201000008520 protoplasmic astrocytoma Diseases 0.000 description 1
210000001938 protoplast Anatomy 0.000 description 1
150000003230 pyrimidines Chemical class 0.000 description 1
229940107700 pyruvic acid Drugs 0.000 description 1
238000010791 quenching Methods 0.000 description 1
230000000171 quenching effect Effects 0.000 description 1
IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
238000002708 random mutagenesis Methods 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
230000008707 rearrangement Effects 0.000 description 1
102000027427 receptor guanylyl cyclases Human genes 0.000 description 1
108091008596 receptor guanylyl cyclases Proteins 0.000 description 1
210000000664 rectum Anatomy 0.000 description 1
230000009467 reduction Effects 0.000 description 1
239000011347 resin Substances 0.000 description 1
229920005989 resin Polymers 0.000 description 1
230000000241 respiratory effect Effects 0.000 description 1
210000002345 respiratory system Anatomy 0.000 description 1
210000000574 retroperitoneal space Anatomy 0.000 description 1
238000004007 reversed phase HPLC Methods 0.000 description 1
201000009410 rhabdomyosarcoma Diseases 0.000 description 1
PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
239000002336 ribonucleotide Substances 0.000 description 1
125000002652 ribonucleotide group Chemical group 0.000 description 1
150000003290 ribose derivatives Chemical group 0.000 description 1
210000003705 ribosome Anatomy 0.000 description 1
229960004889 salicylic acid Drugs 0.000 description 1
210000003079 salivary gland Anatomy 0.000 description 1
201000007416 salivary gland adenoid cystic carcinoma Diseases 0.000 description 1
238000005464 sample preparation method Methods 0.000 description 1
208000014212 sarcomatoid carcinoma Diseases 0.000 description 1
206010039667 schwannoma Diseases 0.000 description 1
230000007017 scission Effects 0.000 description 1
238000013515 script Methods 0.000 description 1
201000008407 sebaceous adenocarcinoma Diseases 0.000 description 1
150000003335 secondary amines Chemical class 0.000 description 1
238000000926 separation method Methods 0.000 description 1
210000000717 sertoli cell Anatomy 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
230000019491 signal transduction Effects 0.000 description 1
230000011664 signaling Effects 0.000 description 1
201000008123 signet ring cell adenocarcinoma Diseases 0.000 description 1
229910052710 silicon Inorganic materials 0.000 description 1
239000010703 silicon Substances 0.000 description 1
150000003376 silicon Chemical class 0.000 description 1
238000002741 site-directed mutagenesis Methods 0.000 description 1
210000003491 skin Anatomy 0.000 description 1
201000002078 skin pilomatrix carcinoma Diseases 0.000 description 1
208000000649 small cell carcinoma Diseases 0.000 description 1
210000000813 small intestine Anatomy 0.000 description 1
210000004872 soft tissue Anatomy 0.000 description 1
238000002764 solid phase assay Methods 0.000 description 1
239000006104 solid solution Substances 0.000 description 1
239000002195 soluble material Substances 0.000 description 1
210000004989 spleen cell Anatomy 0.000 description 1
239000007921 spray Substances 0.000 description 1
206010041823 squamous cell carcinoma Diseases 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
208000028210 stromal sarcoma Diseases 0.000 description 1
230000004960 subcellular localization Effects 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
125000000547 substituted alkyl group Chemical group 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
208000030457 superficial spreading melanoma Diseases 0.000 description 1
239000000829 suppository Substances 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
239000000725 suspension Substances 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
206010042863 synovial sarcoma Diseases 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
239000003826 tablet Substances 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
230000002123 temporal effect Effects 0.000 description 1
ISXSCDLOGDJUNJ-UHFFFAOYSA-N tert-butyl prop-2-enoate Chemical compound CC(C)(C)OC(=O)C=C ISXSCDLOGDJUNJ-UHFFFAOYSA-N 0.000 description 1
150000003512 tertiary amines Chemical class 0.000 description 1
238000012360 testing method Methods 0.000 description 1
210000001550 testis Anatomy 0.000 description 1
229960002180 tetracycline Drugs 0.000 description 1
229930101283 tetracycline Natural products 0.000 description 1
235000019364 tetracycline Nutrition 0.000 description 1
150000003522 tetracyclines Chemical class 0.000 description 1
MUUHXGOJWVMBDY-UHFFFAOYSA-L tetrazolium blue Chemical compound [Cl-].[Cl-].COC1=CC(C=2C=C(OC)C(=CC=2)[N+]=2N(N=C(N=2)C=2C=CC=CC=2)C=2C=CC=CC=2)=CC=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 MUUHXGOJWVMBDY-UHFFFAOYSA-L 0.000 description 1
208000001644 thecoma Diseases 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
125000003396 thiol group Chemical group [H]S* 0.000 description 1
RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
235000008521 threonine Nutrition 0.000 description 1
229940104230 thymidine Drugs 0.000 description 1
229940113082 thymine Drugs 0.000 description 1
210000001541 thymus gland Anatomy 0.000 description 1
229960002175 thyroglobulin Drugs 0.000 description 1
210000001685 thyroid gland Anatomy 0.000 description 1
208000030901 thyroid gland follicular carcinoma Diseases 0.000 description 1
208000015191 thyroid gland papillary and follicular carcinoma Diseases 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
208000029335 trabecular adenocarcinoma Diseases 0.000 description 1
210000003437 trachea Anatomy 0.000 description 1
FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
230000005030 transcription termination Effects 0.000 description 1
238000012546 transfer Methods 0.000 description 1
206010044412 transitional cell carcinoma Diseases 0.000 description 1
230000005945 translocation Effects 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical compound CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 description 1
239000002753 trypsin inhibitor Substances 0.000 description 1
108010044292 tryptophyltyrosine Proteins 0.000 description 1
238000013060 ultrafiltration and diafiltration Methods 0.000 description 1
230000036967 uncompetitive effect Effects 0.000 description 1
241000701161 unidentified adenovirus Species 0.000 description 1
241000701447 unidentified baculovirus Species 0.000 description 1
241001515965 unidentified phage Species 0.000 description 1
238000011144 upstream manufacturing Methods 0.000 description 1
229940035893 uracil Drugs 0.000 description 1
210000000626 ureter Anatomy 0.000 description 1
210000003932 urinary bladder Anatomy 0.000 description 1
210000001215 vagina Anatomy 0.000 description 1
125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
235000013311 vegetables Nutrition 0.000 description 1
229960003048 vinblastine Drugs 0.000 description 1
JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
230000009385 viral infection Effects 0.000 description 1
210000003905 vulva Anatomy 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
238000001262 western blot Methods 0.000 description 1
238000009736 wetting Methods 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1
229940075420 xanthine Drugs 0.000 description 1
210000005253 yeast cell Anatomy 0.000 description 1
239000011701 zinc Substances 0.000 description 1
229910052725 zinc Inorganic materials 0.000 description 1